FEB 14, 2020 5:48 AM PST

Rewired natural killer cells show promising results in leukemia patients

WRITTEN BY: Tara Fernandez

Natural killer (NK) cells are a subset of white blood cells that are key players in the innate immune system, orchestrating host-rejection responses against both cancer cells and virally infected cells. Cancer researchers and drug developers are supercharging NK cells to attack malignant tissues by engineering them to express chimeric antigen receptors (CAR) in a process similar to FDA-approved T cell therapies Yescarta and Kymriah.

In a recent study published in The New England Journal of Medicine, clinical trial data shows promising results in patients with non-Hodgkin’s lymphoma or chronic lymphocytic leukemia that were treated with anti-CD19 CAR NK cells.

Significantly, the treatment was found to be effective while not triggering the flare-up of a common side effect of this type of adoptive immune cell therapy: cytokine release syndrome. 

This systemic inflammatory response, also known as an infusion reaction, is an unwanted complication that occurs when large numbers of activated immune cells are injected into a patient. Symptoms include seizures, fever, nausea, and in serious cases, cytokine release syndrome may even cause fatalities.

In the early data reported from this phase I/II trial, 73 percent of patients showed a positive response to the CAR NK therapy, with the majority of responding patients showing signs of complete remission. These responses occurred within a month after the cell therapy was administered, with CAR NK cells showing signs of persistence in the infused patients up to a year post-treatment.

Corresponding author, Katy Rezvani, MD, Ph.D., professor of stem cell transplantation and cellular therapy at The University of Texas MD Anderson Cancer Center said, “We are encouraged by the results of the clinical trial, which will launch further clinical studies to investigate allogeneic cord blood-derived CAR NK cells as a potential treatment option for patients in need.”

 

Sources: Cancer Network, The New England Journal of Medicine.

 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
MAY 17, 2020
Genetics & Genomics
How Non-Coding Genomic Regions Influence Autoimmune Disease
MAY 17, 2020
How Non-Coding Genomic Regions Influence Autoimmune Disease
Scientists have gained new insight into autoimmune and allergic disorders.
JUN 04, 2020
Clinical & Molecular DX
Low T Cells Linked To High COVID Risk
JUN 04, 2020
Low T Cells Linked To High COVID Risk
  German scientists have found a link between immune cell counts and the risk of developing severe, potentially lif ...
JUL 07, 2020
Immunology
Existing drugs can prevent SARS-CoV-2 from hijacking cells
JUL 07, 2020
Existing drugs can prevent SARS-CoV-2 from hijacking cells
An international team of researchers has analysed how SARS-CoV-2, the virus that causes COVID-19, hijacks the proteins i ...
JUL 29, 2020
Drug Discovery & Development
Will We Have a COVID-19 Vaccine by Year-End?
JUL 29, 2020
Will We Have a COVID-19 Vaccine by Year-End?
This week, pharmaceutical companies Moderna and Pfizer launched giant Phase III 30,000-subject trials for their COVID-19 ...
JUL 29, 2020
Immunology
Immune Variation Explains Different COVID-19 Outcomes
JUL 29, 2020
Immune Variation Explains Different COVID-19 Outcomes
Immune systems respond differently to coronavirus infection. People experience the disease causes by coronavirus, COVID- ...
AUG 05, 2020
Immunology
Intercepting Cancer Cells Before They Can Dodge the Immune System
AUG 05, 2020
Intercepting Cancer Cells Before They Can Dodge the Immune System
The battle that naturally occurs between the body’s immune system and cancerous cells is one that scientists have ...
Loading Comments...